Document Detail


Psoriasis triggered by mefloquine.
MedLine Citation:
PMID:  21137644     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A 46-year-old Caucasian man living on the central Mediterranean island of Gozo (Malta) was started on mefloquine 250 mg once weekly before a trip to lower Egypt. He took his medication 1 week before starting his holiday and was advised to continue it for 4 weeks after returning. He did not take any other medication and enjoyed the holiday, which he initially intended to repeat in the near future. His medical history revealed a number of episodes of psoriasis for which he sought dermatologic advice. He had been given systemic therapy on at least one occasion, but the condition had been fairly quiescent for some time and he had not needed to consult a dermatologist for more than 4 years. Soon after the third tablet of mefloquine and effectively just after his return home to Gozo, the patient noticed that the psoriasis was "creeping back." He noted progressive deterioration in his skin problem but nevertheless finished the recommended course of therapy considering that "being sure about not developing malaria was far more important than a touch of psoriasis." The psoriasis worsened to the extent that he had taken off work for 2 weeks from his job as a self-employed carpenter at the time of referral. On examination, clearly there was a significant flare up of his psoriasis with severe involvement of the hands (Figure 1) and feet and less so over the rest of his body. He had been off work and matters were steadily getting worse in spite of topical treatment with a combination of calcipotriol-betamethasone ointment. Oral methotrexate 15 mg once weekly was commenced together with topical therapy with good results (Figure 2).
Authors:
Joseph L Pace
Related Documents :
7771374 - Medical examiners' attitudes toward organ procurement from child abuse/homicide victims.
1871284 - Water intoxication: a complication of pelvic us in a patient with syndrome of inappropr...
8431254 - Validity of nbme part i and part ii scores for selection of residents in orthopaedic su...
12674944 - Bullying and harassment in perioperative settings.
15669584 - Treating asthma by the guidelines: developing a medication management information syste...
15165274 - Cytopathology in france.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Skinmed     Volume:  8     ISSN:  1540-9740     ISO Abbreviation:  Skinmed     Publication Date:    2010 Sep-Oct
Date Detail:
Created Date:  2010-12-08     Completed Date:  2011-01-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101168327     Medline TA:  Skinmed     Country:  United States    
Other Details:
Languages:  eng     Pagination:  301-2     Citation Subset:  IM    
Affiliation:
University of Malta Medical School, Malta. josephlpace@onvol.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antimalarials / adverse effects*,  therapeutic use
Betamethasone / administration & dosage,  therapeutic use
Calcitriol / administration & dosage,  analogs & derivatives,  therapeutic use
Dermatologic Agents / administration & dosage,  therapeutic use
Drug Therapy, Combination
Humans
Malaria / prevention & control
Male
Mefloquine / adverse effects*,  therapeutic use
Methotrexate / therapeutic use
Middle Aged
Psoriasis / etiology*,  pathology
Severity of Illness Index
Travel
Chemical
Reg. No./Substance:
0/Antimalarials; 0/Dermatologic Agents; 112965-21-6/calcipotriene; 32222-06-3/Calcitriol; 378-44-9/Betamethasone; 53230-10-7/Mefloquine; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Keloid formation occurring in the distribution of a congenital vascular malformation.
Next Document:  Tropical aquarium aquatic dermatoses: bristle worm envenomation.